azetukalner
azetukalner: sourced relationships with 1 company · 10 clinical trials tracked.
azetukalner evidence translation
What we can confirm
10 tracked trials
What it means
What to watch
Prepared research question
How could azetukalner → XENE affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Xenon Pharmaceuticals Inc. (XENE) Focal Epilepsy; Major Depressive Disorder; Focal Onset Seizu… | Phase 2 |
Clinical Trial Registry Records (10)
A Multicenter, Long-term, Open-Label, Safety, Tolerability, and Efficacy Study of Azetukalner in Bipolar I or II Depression
Primary endpoint: Severity and frequency of treatment-emergent adverse events, serious adverse events, adverse events of special interest, and events of clinical interest
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Azetukalner in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Primary endpoint: Change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6.
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in Moderate-to-Severe Major Depressive Disorder
Primary endpoint: Change from baseline in the Hamilton Depression Rating Scale, 17-item (HAMD-17) score at Week 6
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Azetukalner in Major Depressive Disorder
Primary endpoint: Severity and frequency of treatment-emergent adverse events, serious adverse events, adverse events of special interest, and events of clinical interest
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in Moderate-to-Severe Major Depressive Disorder
Primary endpoint: Change from baseline in the Hamilton Depression Rating Scale, 17-item (HAMD-17) score at Week 6
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
Primary endpoint: Median percent change (MPC) in focal seizure frequency from baseline to DBP for XEN1101 versus placebo.
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy
Primary endpoint: The adverse events
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Primary endpoint: Median percent change (MPC) in monthly (28 days) PGTCS frequency
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
Primary endpoint: Median percent change (MPC) in monthly (28 days) focal seizure frequency from baseline to DBP for XEN1101 versus placebo.
A Proof-of-Concept, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 in Major Depressive Disorder
Primary endpoint: Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Score.
Frequently asked questions
Which companies have sourced relationships with azetukalner?
azetukalner has dated SEC/FDA relationship records for Xenon Pharmaceuticals Inc..
How many clinical trials involve azetukalner?
BioSniper tracks 10 clinical trials involving azetukalner.